STOCK TITAN
  1. Home
  2. News
  3. IXHL

Incannex Healthcare Inc - ixhl STOCK NEWS

Welcome to our dedicated news page for Incannex Healthcare (Ticker: ixhl), a resource for investors and traders seeking the latest updates and insights on Incannex Healthcare.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Incannex Healthcare's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Incannex Healthcare's position in the market.

News
Incannex Healthcare Inc. Quarterly Update, Q1 2024
Rhea-AI Summary
Incannex Healthcare Inc. provides a quarterly update for Q1 2024, highlighting progress in their pharmaceutical development programs for cannabinoid products and psychedelic therapies. Key projects include IHL-42X for Obstructive Sleep Apnea, IHL-675A for Rheumatoid Arthritis, and PsiGAD for Generalised Anxiety Disorder. The company is focused on advancing clinical trials, preparing for FDA submissions, and opening Clarion Clinics for psychedelic-assisted therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.3%
Tags
earnings
-
News
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder
Rhea-AI Summary
Incannex Healthcare Inc. (Nasdaq: IXHL) announces positive Phase 2 results for psilocybin in generalised anxiety disorder. The PsiGAD1 trial achieved its primary endpoint with a significant HAM-A reduction of 12.8 points, surpassing expectations. Psilocybin group showed 44% improvement and 27% remission rate, far exceeding placebo. Psilocybin was well-tolerated with no severe adverse events. IND application for Phase 2B trial submitted to FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
48.58%
Tags
clinical trial
-
News
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation
Rhea-AI Summary
Incannex Healthcare Inc. (Nasdaq: IXHL) successfully completes pre-IND meeting with the FDA for CannQuit-N, a tobacco smoking cessation drug, receiving positive feedback and guidance for clinical trial design and manufacturing strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.68%
Tags
none
News
Clarion Clinics Open for Psychedelic-Assisted Treatments
Rhea-AI Summary
Incannex Healthcare Inc (Nasdaq: IXHL) is pleased to announce that Clarion Clinic’s Head of Psychiatry, Professor Suresh Sundram, has been approved by the TGA to prescribe MDMA for Post-traumatic Stress Disorder and psilocybin for Treatment-resistant Depression. The clinic in Melbourne is now open and represents Australia’s leading track record in psychedelic-assisted therapies. The TGA down-scheduled MDMA and psilocybin for use in the treatment of PTSD and TRD, permitting their use in clinical service delivery through the Authorised Prescriber Scheme.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.4%
Tags
none
-
News
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis
Rhea-AI Summary
Incannex Healthcare Inc. (Nasdaq: IXHL) has announced the commencement of patient dosing in the Phase 2 clinical trial for IHL-675A, a combination drug candidate for rheumatoid arthritis. The trial aims to assess pain and function relative to baseline and will enroll 128 participants across 10 study sites in Australia. IHL-675A is a proprietary combination of Hydroxychloroquine Sulphate and cannabidiol, with well-characterized anti-inflammatory activity. The trial will monitor safety and efficacy outcomes, including inflammatory biomarkers and joint inflammation and damage via MRI. IHL-675A is a potential treatment for other inflammatory conditions such as inflammatory bowel disease, COPD, and asthma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
clinical trial
-
News
Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences
Rhea-AI Summary
Incannex Healthcare Inc. completed dosing and treatment protocols for all 72 participants in the PsiGAD-1 clinical trial evaluating its psilocybin treatment program for patients with generalized anxiety disorder. The company anticipates topline results within Q1 2024 and is well-advanced in the FDA IND application process. An independent documentary covering Monash Clinical Psychedelic Lab and PsiGAD research program will be released by SBS television network in late February 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
clinical trial
News
Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
Rhea-AI Summary
Incannex Healthcare Inc. (Nasdaq: IXHL) has received IRB approval for the protocol of its Phase 2/3 clinical trial for the drug candidate IHL-42X to treat obstructive sleep apnea (OSA). The trial will assess safety and efficacy in OSA patients who are intolerant, non-compliant, or naïve to positive airway pressure (PAP). The study aims to recruit at least 560 patients across the United States, Germany, Spain, and Finland. The Phase 2/3 trial has already begun startup with 24 sites selected in the United States, 13 in Germany, 4 in Spain, and 2 in Finland. IHL-42X has shown promising results in a Phase 2 proof-of-concept study, reducing the apnea hypopnea index (AHI) by over 50% at the optimal dose, improving oxygen desaturation index, sleep efficiency, and patient-reported sleep quality.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
clinical trial
-
News
Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia
Rhea-AI Summary
Incannex Healthcare Ltd (Nasdaq: IXHL) has received Human Research Ethics Committee (HREC) endorsement for administration of psychedelic-assisted therapies for TRD and PTSD. The Melbourne clinic fit-out is complete, and the clinical and administrative teams are in place. The clinic is the first dedicated Psychedelic-assisted therapy clinic in Australia and has received a substantial number of expressions of interest in treatment submissions from potential patients since opening its application process earlier this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
none
-
News
Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea
Rhea-AI Summary
Incannex Healthcare Inc. (Nasdaq: IXHL) is developing IHL-42X, a promising drug candidate for obstructive sleep apnea (OSA) treatment. The drug has shown significant efficacy in reducing apnea hypopnea index (AHI) in Phase 2 clinical trials, with potential to address a market of 936 million affected adults worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.45%
Tags
clinical trial
News
Incannex Healthcare Announces Completion of its Redomiciliation to the United States
Rhea-AI Summary
Incannex Healthcare Inc. (NASDAQ: IXHL) successfully completed its redomiciliation from Australia to the United States, with shares of common stock expected to commence trading on Nasdaq under the symbol 'IXHL' on November 30, 2023. The company will now be subject to the reporting requirements of the SEC and corporate governance rules of Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock IXHL logo
Incannex Healthcare Inc

Nasdaq:IXHL

IXHL Rankings

#4859 Ranked by Market Cap
#5228 Ranked by Stock Gains
N/A Ranked by Dividends

IXHL Stock Data

47.29M
12.79M
21.54%
6.39%
0.56%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Australia
Sydney